ArticleFrontiers in oncology2022

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.

Yun-Tse Chou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.